Tarsus Pharmaceuticals (TARS) Gross Margin (2021 - 2026)
Tarsus Pharmaceuticals' (TARS) quarterly Gross Margin came in at 94.2% in Q1 2026, up 85.0% year-on-year from 50.92% in Q1 2025, and up 1.52% quarter-over-quarter from 92.8% in Q4 2025.
Tarsus Pharmaceuticals (TARS) Gross Margin (2021 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Gross Margin history runs 6 years deep, the most recent figure standing at 94.2% for Q1 2026.
- On a quarterly basis, Gross Margin rose 85.0% year-over-year to 94.2% in Q1 2026; TTM through Mar 2026 was 93.48%, a 49.0% increase from a year earlier, with the FY2025 full-year figure at 93.2%, up 21.0% from the prior year.
- Gross Margin climbed to 94.2% in Q1 2026 per TARS's latest filing, from 92.8% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q1 2023 and bottomed at 79.85% in Q3 2023.
- The 5-year median for Gross Margin is 93.35% (2025), against an average of 93.12%.
- Across the five-year window, Gross Margin slumped 1110 bps in 2022 and surged 1341 bps in 2024, its largest moves.
- Year by year, Gross Margin stood at 96.0% in 2022, then decreased by 6 bps to 90.7% in 2023, then rose by 2 bps to 92.58% in 2024, then advanced by 0 bps to 92.8% in 2025, then advanced by 2 bps to 94.2% in 2026.
- Per Business Quant, the three latest TARS Gross Margin figures stand at 94.2% (Q1 2026), 92.8% (Q4 2025), and 93.0% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Tarsus Pharmaceuticals | 2.52 Bn | 2.41 Bn | 152.66 Mn | 94.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.20% |
| Dec 31, 2025 | 92.80% |
| Sep 30, 2025 | 93.00% |
| Jun 30, 2025 | 93.92% |
| Mar 31, 2025 | 93.35% |
| Dec 31, 2024 | 92.58% |
| Sep 30, 2024 | 93.26% |
| Jun 30, 2024 | 92.64% |
| Mar 31, 2024 | 94.01% |
| Dec 31, 2023 | 90.70% |
| Sep 30, 2023 | 79.85% |
| Mar 31, 2023 | 100.00% |
| Dec 31, 2022 | 96.00% |
| Jun 30, 2022 | 96.58% |
| Mar 31, 2022 | 93.88% |
| Dec 31, 2021 | 107.10% |
| Sep 30, 2021 | 94.76% |
| Jun 30, 2021 | 96.65% |
| Mar 31, 2021 | 96.12% |